MedTrace Logo

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

NCT02182986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 944

Last updated 2019-08-29

No results posted yet for this study

Summary

Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).

Conditions

  • Heart Transplant
  • Small Intestine Transplant
  • Kidney Transplant
  • Liver Transplant
  • EBV-Related PTLD
  • PTLDs

Interventions

PROCEDURE

transplant

All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).

DRUG

Immunosuppressive Drugs

Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.

Sponsors & Collaborators

  • Clinical Trials in Organ Transplantation in Children

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Carlos Esquivel, M.D., Ph.D. · Stanford University

  • Daniel Bernstein, M.D. · Stanford University

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-14
Primary Completion
2019-05-15
Completion
2019-05-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02182986 on ClinicalTrials.gov